Gene Therapy Offers Hope for Ophthalmology: San Severino Leads Rare Disease Research
- August 18, 2025 - In a landmark achievement for ophthalmology, a team at the Luigi Vanvitelli University of Naples has successfully administered a novel gene therapy for Usher...
- Usher syndrome type 1B is characterized by profound congenital deafness adn retinitis pigmentosa, a progressive eye disease leading to vision loss.
- Gene therapy aims to treat diseases by correcting faulty genes.
Groundbreaking Gene Therapy Restores Sight, Offers Hope for Usher Syndrome Patients
Table of Contents
A World First in Naples: Pioneering Treatment for Usher 1B Syndrome
August 18, 2025 – In a landmark achievement for ophthalmology, a team at the Luigi Vanvitelli University of Naples has successfully administered a novel gene therapy for Usher type 1B syndrome. This marks the first time this innovative treatment has been used globally, offering a beacon of hope for individuals living wiht this rare, inherited condition.
Usher syndrome type 1B is characterized by profound congenital deafness adn retinitis pigmentosa, a progressive eye disease leading to vision loss. The therapy, developed by the Telethon Institute of Genetics and Medicine in Pozzuoli, Italy, targets the underlying genetic defect responsible for the condition.
The Science Behind the Breakthrough: Overcoming Genetic Hurdles
Gene therapy aims to treat diseases by correcting faulty genes. This often involves delivering a functional copy of the gene or a compensating gene into the patient’s cells using viral vectors – harmless viruses engineered to carry therapeutic genetic material. Though, the myo7a gene, responsible for Usher 1B syndrome, is unusually large, presenting a significant challenge for traditional viral delivery methods.
To overcome this obstacle,the Naples team employed a clever strategy. They utilized two separate viral vectors, each carrying a portion of the genetic data needed to produce the missing protein in patients with Usher 1B. This innovative approach successfully delivered the complete gene sequence, paving the way for potential vision restoration.
Early Results and Future Implications
Initial results from the treatment are highly encouraging. The first patient treated, a 38-year-old individual, demonstrated a “considerable enhancement in visual acuity” within weeks of receiving the gene therapy. These findings confirm the safety and tolerability of the procedure, and suggest a promising therapeutic effect.
Vittorio Pirani, a specialist at the center of excellence in San Severino, Asti, emphasized the broader implications of this work. “The experience of Naples…offers new hopes for the gene therapy also of other pathologies,” he stated. The team’s success builds upon previous advancements in gene therapy for retinal diseases, such as the treatment for RPE65-related vision loss, and provides a valuable framework for tackling other genetic eye conditions.